
  
    
      
        Background_NNP
        Mivacurium_NNP is_VBZ a_DT short_JJ acting_NN benzylisoquinoline_NN
        non-depolarizing_JJ neuromuscular_NN blocking_VBG agent_NN ,_, with_IN a_DT
        demonstrated_VBN safety_NN and_CC efficacy_NN both_DT in_IN children_NNS and_CC
        adults_NNS [_NN 1_CD 2_CD 3_CD ]_NN ._. It_PRP has_VBZ been_VBN in_IN clinical_JJ use_NN for_IN a_DT long_JJ
        time_NN and_CC the_DT clinical_JJ pharmacology_NN has_VBZ been_VBN widely_RB
        documented_VBN ._.
        In_IN children_NNS ,_, administration_NN of_IN isoflurane_NN previous_JJ to_TO
        and_CC during_IN the_DT effect_NN of_IN vecuronium_NN or_CC mivacurium_NN increases_VBZ
        their_PRP$ spontaneous_JJ recovery_NN times_NNS in_IN a_DT time-dependent_JJ manner_NN
        [_NN 4_CD 5_CD ]_NN ._. However_RB ,_, these_DT times_NNS are_VBP not_RB modified_VBN if_IN the_DT
        anesthetic_JJ gas_NN is_VBZ administered_VBN after_IN the_DT peak_NN effect_NN of_IN the_DT
        neuromuscular_NN relaxant_NN is_VBZ produced_VBN [_NN 6_CD ]_NN ._.
        Furthermore_RB ,_, despite_IN infants_NNS usually_RB respond_VBP differently_RB
        to_TO the_DT effects_NNS of_IN a_DT neuromuscular_NN relaxant_NN from_IN children_NNS or_CC
        adults_NNS do_VBP ,_, and_CC that_DT isoflurane_NN is_VBZ commonly_RB used_VBN in_IN children_NNS
        including_VBG infants_NNS ,_, only_RB few_JJ studies_NNS have_VBP evaluated_VBN the_DT
        effect_NN of_IN mivacurium_NN during_IN isoflurane_NN anesthesia_NN [_NN 4_CD 7_CD 8_CD ]_NN
        ._.
        In_IN the_DT current_JJ study_NN ,_, we_PRP compared_VBD the_DT effect_NN of_IN 200_CD and_CC
        250_CD μg_NN /_NN kg_NN of_IN mivacurium_NN in_IN infants_NNS during_IN isoflurane_NN
        anesthesia_NN in_IN order_NN to_TO investigate_VB whether_IN the_DT higher_JJR dose_NN
        resulted_VBD in_IN a_DT faster_JJR onset_NN of_IN action_NN ._. Spontaneous_NNP recovery_NN
        times_NNS and_CC cardiovascular_JJ response_NN to_TO the_DT neuromuscular_NN
        relaxant_NN were_VBD also_RB compared_VBN ._.
      
      
        Methods_NNP
        
          Measurements_NNP and_CC outcomes_NNS
          For_IN analysis_NN of_IN the_DT effect_NN ,_, the_DT neuromuscular_NN response_NN
          was_VBD divided_VBN in_IN two_CD phases_NNS ._. Response_NNP from_IN the_DT baseline_NN
          until_IN the_DT maximal_NN relaxation_NN was_VBD observed_VBN and_CC maintained_VBN
          was_VBD used_VBN to_TO compute_VB the_DT times_NNS to_TO a_DT block_NN of_IN 90_CD (_( OA_NNP 
          90_CD )_) and_CC 99_CD ._. 9_CD %_NN (_( OA_NNP 
          100_CD )_) ._. Second_JJ ,_, response_NN starting_VBG with_IN
          the_DT maximal_NN relaxation_NN until_IN it_PRP returned_VBD to_TO baseline_NN
          values_NNS was_VBD used_VBN to_TO obtain_VB the_DT times_NNS to_TO spontaneous_JJ
          recovery_NN of_IN 10_CD ,_, 25_CD ,_, 50_CD ,_, 75_CD and_CC 90_CD %_NN of_IN the_DT neuromuscular_NN
          function_NN ._. To_TO obtain_VB these_DT parameters_NNS ,_, both_DT T_NN and_CC T_NN 4_CD /_NN T_NN 1_CD
          responses_NNS were_VBD analyzed_VBN ._.
          The_DT time-course_JJ of_IN T_NN or_CC T_NN 4_CD /_NN T_NN 1_CD in_IN each_DT phase_NN was_VBD
          considered_VBN sigmoidally_RB related_VBN to_TO time_NN ,_, and_CC equation_NN used_VBN
          to_TO fit_VB them_PRP was_VBD the_DT following_VBG [_NN 13_CD ]_NN :_:
          
          The_DT model_NN used_VBN is_VBZ a_DT logistic_JJ equation_NN where_WRB E_NNP =_SYM the_DT
          observed_VBN response_NN ,_, 
          t_NN =_SYM the_DT time_NN at_IN which_WDT every_DT
          response_NN was_VBD registered_VBN ,_, E_NNP 
          0_CD =_SYM response_NN at_IN zero_CD time_NN ,_, b_SYM =_SYM slope_NN
          factor_NN ,_, 
          t_NN 
          50_CD =_SYM time_NN at_IN which_WDT half-maximal_JJ
          response_NN is_VBZ given_VBN ,_, and_CC E_NNP 
          max_NN =_SYM maximal_NN response_NN ._. In_IN all_DT
          patients_NNS the_DT maximal_NN block_NN and_CC maximal_NN recovery_NN were_VBD >_NN
          96_CD %_NN ._. Therefore_RB the_DT E_NNP 
          max_NN was_VBD obtained_VBN by_IN transforming_VBG the_DT
          maximal_NN effect_NN registered_VBN by_IN the_DT TOF-Guard_NNP into_IN the_DT 100_CD %_NN ,_,
          a_DT value_NN fixed_VBN into_IN the_DT model_NN ._. All_DT the_DT other_JJ values_NNS of_IN the_DT
          effect_NN were_VBD then_RB transformed_VBN according_VBG to_TO the_DT new_JJ 100_CD %_NN ._.
          Value_NNP of_IN the_DT E_NNP 
          0_CD was_VBD then_RB also_RB fixed_VBN to_TO the_DT model_NN ._.
          The_DT complete_JJ neuromuscular_NN response_NN was_VBD fitted_JJ to_TO time_NN by_IN
          using_VBG the_DT SigmaPlot_NNP 4_CD ._. 01_CD (_( SPSS_NNP México_NNP ,_, Mexico_NNP City_NNP ,_,
          Mexico_NNP )_) for_IN Windows_NNP ™_NN 95_CD ,_, and_CC b_SYM and_CC 
          t_NN 
          50_CD were_VBD computed_JJ by_IN iteration_NN ._.
          Thereafter_RB ,_, calculated_VBN effect_NN was_VBD obtained_VBN by_IN proper_JJ
          arrangement_NN of_IN the_DT equation_NN described_VBD above_IN ._. For_IN each_DT
          patient_NN ,_, the_DT HR_NNP and_CC SBP_NNP and_CC DBP_NNP were_VBD transformed_VBN into_IN the_DT
          area_NN under_IN the_DT heart_NN rate-time_JJ curve_NN (_( AUC-HR_NNP )_) ,_, and_CC into_IN
          the_DT area_NN under_IN systolic_JJ and_CC diastolic_JJ blood_NN pressure-time_JJ
          curve_NN (_( AUC-SBP_NNP and_CC AUC-DBP_NNP ,_, respectively_RB )_) ._. Each_DT AUC_NNP was_VBD
          obtained_VBN with_IN data_NNS obtained_VBN immediately_RB after_IN mivacurium_NN
          was_VBD administered_VBN until_IN 30_CD min_NN ._. The_DT AUC_NNP 's_POS were_VBD computed_JJ by_IN
          means_NNS of_IN the_DT Microsoft_NNP ®_NN Excel_NNP 97_CD using_VBG an_DT adaptation_NN of_IN a_DT
          standard_JJ procedure_NN [_NN 14_CD ]_NN ,_, as_IN follows_VBZ :_:
          
          where_WRB Y_NNP represents_VBZ HR_NNP ,_, SBP_NNP or_CC DBP_NNP ,_, the_DT X_NNP is_VBZ the_DT time_NN
          at_IN which_WDT Y_NNP was_VBD measured_VBN ,_, and_CC 1_CD ,_, 2_CD ._. ._. ._. n_NN are_VBP the_DT progressive_JJ
          values_NNS until_IN the_DT last_JJ observation_NN was_VBD performed_VBN ._. By_IN using_VBG
          this_DT equation_NN ,_, the_DT overall_JJ response_NN of_IN HR_NNP ,_, SBP_NNP and_CC DBP_NNP is_VBZ
          obtained_VBN and_CC compared_VBN between_IN groups_NNS ,_, avoiding_VBG the_DT
          time-by-time_JJ comparisons_NNS ._.
          Finally_RB ,_, the_DT onset_NN of_IN action_NN was_VBD considered_VBN as_IN the_DT
          primary_JJ outcome_NN of_IN the_DT study_NN while_IN spontaneous_JJ recovery_NN
          times_NNS and_CC cardiovascular_JJ response_NN as_IN secondary_JJ
          outcomes_NNS ._.
        
        
          Statistical_NNP analysis_NN
          All_DT data_NNS were_VBD presented_VBN as_IN mean_NN ±_NN SD_NNP ,_, ranges_VBZ and_CC when_WRB
          indicated_VBD the_DT 95_CD %_NN confidence_NN intervals_NNS for_IN the_DT difference_NN
          for_IN parametric_JJ data_NNS were_VBD computed_JJ ._. The_DT Student_NNP 
          t_NN test_NN was_VBD used_VBN to_TO compare_VB age_NN and_CC
          weight_NN between_IN the_DT two_CD groups_NNS of_IN treatment_NN ,_, while_IN the_DT
          Fisher_NNP exact_JJ test_NN was_VBD used_VBN for_IN comparison_NN of_IN gender_NN ._. The_DT
          quality_NN of_IN fit_NN of_IN the_DT pharmacodynamic_JJ (_( sigmoidal_NN )_) model_NN
          to_TO the_DT data_NNS was_VBD judged_VBN by_IN correlation_NN coefficient_NN of_IN
          observed_VBD to_TO predicted_VBD effect_NN automatically_RB computed_JJ by_IN
          SigmaPlot_NNP ®_NN ._. Visual_NNP examination_NN of_IN plots_NNS of_IN the_DT ratio_NN of_IN
          observed_VBD to_TO predicted_VBD response_NN and_CC plots_NNS of_IN observed_VBD 
          minus_CC predicted_VBD response_NN in_IN
          function_NN of_IN time_NN was_VBD also_RB performed_VBN ,_, considering_VBG a_DT good_JJ
          agreement_NN between_IN observed_VBD and_CC predicted_VBD response_NN when_WRB
          ratios_NNS approached_VBD 1_CD and_CC differences_NNS approached_VBD 0_CD ._.
          The_DT times_NNS to_TO OA_NNP and_CC to_TO spontaneous_JJ recovery_NN of_IN
          neuromuscular_NN function_NN were_VBD also_RB compared_VBN between_IN groups_NNS
          by_IN the_DT unpaired_JJ Student_NNP 
          t_NN test_NN ._. The_DT unpaired_JJ Student_NNP 
          t_NN test_NN was_VBD also_RB used_VBN to_TO compare_VB
          each_DT AUC_NNP ,_, i_NNP ._. e_SYM ._. AUC-HR_NNP ,_, AUC-SBP_NNP and_CC AUC-DBP_NNP ,_, between_IN
          groups_NNS ._.
        
        
          Ancillary_NNP analyses_NNS
          In_IN every_DT group_NN ,_, the_DT HR_NNP and_CC SBP_NNP and_CC DBP_NNP data_NNS obtained_VBD 5_CD
          min_NN after_IN mivacurium_NN was_VBD administered_VBN were_VBD compared_VBN to_TO
          their_PRP$ respective_JJ baseline_NN values_NNS by_IN means_NNS of_IN the_DT paired_VBN
          Student_NNP 
          t_NN test_NN ._. In_IN order_NN to_TO evaluate_VB the_DT
          effect_NN of_IN age_NN and_CC weight_NN into_IN onset_NN and_CC recovery_NN times_NNS
          (_( data_NNS from_IN all_DT children_NNS )_) ,_, a_DT single_JJ linear_JJ regression_NN
          analysis_NN (_( y_NN =_SYM mx_NN +_NN b_SYM )_) was_VBD performed_VBN between_IN each_DT of_IN the_DT
          onset_NN and_CC recovery_NN times_NNS as_IN the_DT dependent_JJ or_CC explained_VBD
          variable_NN and_CC age_NN or_CC weight_NN as_IN the_DT independent_JJ
          variable_NN ._.
          Finally_RB ,_, descriptive_JJ statistics_NNS ,_, paired_VBN and_CC unpaired_JJ
          Student_NNP 
          t_NN test_NN and_CC linear_JJ regression_NN
          analysis_NN were_VBD performed_VBN using_VBG the_DT software_NN WinSTAT_NNP (_( R_NN ._.
          Fitch_NNP Software_NNP ,_, Cambridge_NNP ,_, MA_NNP ,_, USA_NNP )_) for_IN Microsoft_NNP ®_NN Excel_NNP ._.
          A_DT two-tailed_JJ probability_NN of_IN p_NN <_NN 0_CD ._. 05_CD was_VBD considered_VBN
          significant_JJ in_IN every_DT test_NN or_CC analysis_NN ._.
        
      
      
        Results_NNS
        The_DT two_CD groups_NNS were_VBD similar_JJ in_IN demographic_JJ data_NNS
        including_VBG gender_NN ,_, age_NN and_CC weight_NN (_( Table_NNP 1_LS )_) ,_, reflecting_VBG a_DT
        successful_JJ randomized_JJ procedure_NN ._. All_DT patients_NNS reached_VBD the_DT
        maximal_NN (_( 100_CD %_NN )_) relaxation_NN response_NN and_CC received_VBD a_DT Fahey_NNP
        scale_NN 0_CD for_IN tracheal_NN intubation_NN ,_, and_CC were_VBD extubated_JJ and_CC
        discharged_VBN from_IN the_DT operating_VBG room_NN with_IN a_DT full_JJ recovery_NN of_IN
        the_DT neuromuscular_NN function_NN (_( T_NN ≥_NN 95_CD %_NN )_) and_CC without_IN any_DT
        complication_NN of_IN drug_NN administration_NN ._. All_DT infants_NNS completed_VBD
        the_DT study_NN and_CC data_NNS were_VBD analyzed_VBN in_IN the_DT group_NN they_PRP were_VBD
        randomized_JJ (_( Figure_NN 1_LS )_) ._.
        Responses_NNS from_IN all_DT patients_NNS were_VBD successfully_RB modeled_VBN ._.
        This_DT was_VBD proved_VBN by_IN regression_NN coefficients_NNS always_RB greater_JJR
        than_IN 96_CD %_NN ,_, by_IN plots_NNS of_IN ratio_NN of_IN observed_VBD to_TO predicted_VBD
        response_NN in_IN function_NN of_IN time_NN approaching_VBG 1_CD ,_, and_CC plots_NNS of_IN
        observed_VBD 
        minus_CC predicted_VBD response_NN in_IN function_NN
        of_IN time_NN approaching_VBG 0_CD ._. The_DT times_NNS to_TO OA_NNP and_CC to_TO spontaneous_JJ
        recovery_NN of_IN T_NN and_CC T_NN 4_CD /_NN T_NN 1_CD of_IN the_DT two_CD groups_NNS were_VBD summarized_VBD
        in_IN Tables_NNP 2_CD and_CC 3_CD ,_, respectively_RB ._. In_IN relation_NN to_TO T_NN response_NN
        (_( Table_NNP 2_LS )_) ,_, the_DT maximal_NN block_NN with_IN mivacurium_NN 250_CD μg_NN /_NN kg_NN
        appeared_VBD one_CD minute_NN faster_JJR than_IN 200_CD μg_NN /_NN kg_NN (_( p_NN <_NN 0_CD ._. 05_CD )_) ,_,
        whereas_IN spontaneous_JJ recovery_NN times_NNS were_VBD similar_JJ between_IN
        groups_NNS ._. However_RB ,_, analyzing_VBG T_NN 4_CD /_NN T_NN 1_CD response_NN ,_, similar_JJ times_NNS to_TO
        OA_NNP and_CC to_TO spontaneous_JJ recovery_NN were_VBD obtained_VBN with_IN both_DT
        doses_NNS (_( Table_NNP 3_LS )_) ._. Additionally_RB ,_, no_DT relationship_NN between_IN age_NN
        or_CC weight_NN and_CC any_DT of_IN the_DT OA_NNP or_CC spontaneous_JJ recovery_NN times_NNS
        was_VBD demonstrated_VBN by_IN linear_JJ regression_NN analysis_NN ._.
        In_IN relation_NN to_TO the_DT cardiovascular_JJ response_NN ,_, the_DT AUC-HR_NNP
        was_VBD similar_JJ in_IN the_DT two_CD groups_NNS (_( p_NN >_NN 0_CD ._. 05_CD )_) while_IN both_DT
        AUC-SBP_NNP and_CC AUC-DBP_NNP were_VBD significantly_RB lower_JJR (_( p_NN <_NN 0_CD ._. 05_CD )_)
        in_IN patients_NNS receiving_VBG 250_CD μg_NN /_NN kg_NN ._. The_DT HR_NNP at_IN 5_CD min_NN after_IN any_DT
        dose_NN of_IN mivacurium_NN was_VBD administered_VBN significantly_RB increased_VBN
        in_IN relation_NN to_TO baseline_NN values_NNS (_( p_NN <_NN 0_CD ._. 05_CD )_) ,_, while_IN a_DT
        similar_JJ time-course_JJ of_IN the_DT HR_NNP was_VBD observed_VBN with_IN the_DT two_CD
        doses_NNS of_IN mivacurium_NN (_( Figure_NN 2_LS )_) ._. The_DT time-course_JJ of_IN both_DT SBP_NNP
        (_( Figure_NN 3_LS )_) and_CC DBP_NNP (_( Figure_NN 4_LS )_) reflected_VBD the_DT differences_NNS
        observed_VBD in_IN their_PRP$ respective_JJ AUC_NNP 's_POS ._. Transient_NNP flushing_VBG was_VBD
        observed_VBN in_IN two_CD cases_NNS :_: one_CD female_JJ patient_NN ,_, weighing_VBG 13_CD kg_NN ,_,
        aged_VBN 22_CD mo_NN ._. ,_, and_CC receiving_VBG mivacurium_NN 200_CD μg_NN /_NN kg_NN ,_, and_CC one_CD
        male_JJ patient_NN ,_, weighing_VBG 8_CD ._. 3_CD kg_NN ,_, aged_VBN 8_CD mo_NN ._. ,_, and_CC receiving_VBG
        mivacurium_NN 250_CD μg_NN /_NN kg_NN ._.
      
      
        Discussion_NNP
        In_IN this_DT study_NN patients_NNS underwent_VBD muscle_NN relaxation_NN with_IN
        mivacurium_NN ._. Anesthesia_NNP was_VBD intravenously_RB induced_VBN and_CC
        maintained_VBN with_IN isoflurane_NN administered_VBN when_WRB relaxation_NN had_VBD
        reached_VBN a_DT maximal_NN response_NN ._. The_DT same_JJ clinical_JJ model_NN was_VBD
        previously_RB used_VBN to_TO evaluate_VB the_DT effects_NNS of_IN rocuronium_NN [_NN 6_CD ]_NN
        ,_, and_CC clearly_RB differs_VBZ from_IN other_JJ studies_NNS ._. Mainly_RB ,_,
        intubation_NN followed_VBN by_IN gas_NN administration_NN was_VBD performed_VBN
        after_IN a_DT maximum_NN neuromuscular_NN block_NN was_VBD present_JJ ,_, avoiding_VBG
        any_DT effect_NN of_IN the_DT anesthetic_JJ gas_NN on_IN the_DT times_NNS to_TO OA_NNP ._.
        However_RB ,_, isoflurane_NN is_VBZ able_JJ to_TO increase_VB twice_RB the_DT
        spontaneous_JJ recovery_NN of_IN vecuronium_NN in_IN children_NNS ,_, and_CC
        prolongs_NNS recovery_NN times_NNS for_IN more_JJR than_IN 50_CD %_NN after_IN 30_CD min_NN of_IN
        its_PRP$ administration_NN [_NN 4_CD 5_CD ]_NN ._. In_IN the_DT present_JJ study_NN similar_JJ
        spontaneous_JJ recovery_NN was_VBD observed_VBN in_IN the_DT two_CD groups_NNS ,_, and_CC
        our_PRP$ results_NNS are_VBP comparable_JJ to_TO 15_CD -_: 20_CD min_NN for_IN T_NN 
        90_CD of_IN Goudsouzian_NNP 's_POS review_NN article_NN [_NN 3_CD ]_NN
        ._. Furthermore_RB ,_, our_PRP$ T_NN 
        25_CD values_NNS are_VBP longer_RBR than_IN those_DT obtained_VBN
        with_IN 300_CD μg_NN /_NN kg_NN of_IN mivacurium_NN under_IN nitrous_JJ oxide-halothane_JJ
        or_CC nitrous_JJ oxide-opioid_JJ anesthesia_NN [_NN 15_CD ]_NN ._. These_DT
        considerations_NNS suggest_VBP that_DT isoflurane_NN does_VBZ affect_VB the_DT
        spontaneous_JJ recovery_NN similar_JJ to_TO or_CC higher_JJR than_IN other_JJ
        anesthetic_JJ techniques_NNS ._.
        The_DT duration_NN of_IN action_NN of_IN some_DT non-depolarizing_JJ
        neuromuscular_NN blocking_VBG agents_NNS differs_VBZ with_IN age_NN ,_, even_RB when_WRB
        administered_VBN in_IN equipotent_NN doses_NNS [_NN 16_CD ]_NN ._. Other_JJ studies_NNS
        have_VBP also_RB demonstrated_VBN age_NN differences_NNS of_IN response_NN to_TO
        mivacurium_NN [_NN 4_CD 7_CD 14_CD 17_CD 18_CD ]_NN ._. In_IN the_DT current_JJ study_NN ,_, we_PRP
        obtained_VBD no_DT significant_JJ relationship_NN between_IN age_NN or_CC weight_NN
        and_CC any_DT of_IN the_DT OA_NNP or_CC spontaneous_JJ recovery_NN ._. The_DT range_NN of_IN 6_CD
        to_TO 24_CD months_NNS of_IN our_PRP$ patients_NNS could_MD be_VB broad_JJ to_TO study_VB the_DT
        effect_NN of_IN age_NN in_IN 24_CD patients_NNS ._. However_RB ,_, a_DT Canadian_JJ group_NN of_IN
        pediatric_JJ anesthesiologists_NNS found_VBD similar_JJ neuromuscular_NN
        effects_NNS of_IN mivacurium_NN in_IN patients_NNS aged_VBN between_IN 2_CD mo_NN ._. to_TO 10_CD
        yr_NN ._. [_NN 19_CD 20_CD ]_NN ,_, supporting_VBG our_PRP$ results_NNS ._.
        Additionally_RB ,_, extremely_RB wide_JJ ranges_NNS of_IN neuromuscular_NN
        response_NN in_IN children_NNS have_VBP been_VBN described_VBN for_IN other_JJ
        neuromuscular_NN blocking_VBG ,_, e_SYM ._. g_SYM ._. T_NN 
        75_CD ranged_VBD from_IN 27_CD ._. 3_LS to_TO 91_CD ._. 4_LS min_NN with_IN
        rocuronium_NN 800_CD μg_NN /_NN kg_NN and_CC T_NN 
        25_CD -_: 75_CD ranged_VBD from_IN 6_CD ._. 0_CD -_: 22_CD ._. 8_CD min_NN with_IN
        rocuronium_NN 600_CD μg_NN /_NN kg_NN [_NN 6_CD 21_CD ]_NN ._. In_IN relation_NN to_TO mivacurium_NN ,_,
        cholinesterase_NN activity_NN level_NN is_VBZ a_DT major_JJ determinant_NN of_IN the_DT
        spontaneous_JJ recovery_NN of_IN mivacurium_NN in_IN pediatric_JJ population_NN
        [_NN 8_CD 22_CD ]_NN ._. We_PRP did_VBD not_RB quantify_VB enzyme_NN levels_NNS and_CC therefore_RB
        the_DT inter-individual_JJ variations_NNS of_IN spontaneous_JJ recovery_NN
        times_NNS are_VBP difficult_JJ to_TO be_VB interpreted_VBN ._. However_RB ,_, coefficient_NN
        of_IN variations_NNS of_IN T_NN response_NN to_TO mivacurium_NN varied_VBD from_IN 14_CD ._. 8_CD
        to_TO 45_CD ._. 8_CD %_NN and_CC T_NN 
        75_CD response_NN ranged_VBD from_IN 8_CD ._. 9_CD to_TO 20_CD min_NN ,_,
        representing_VBG a_DT less_RBR markedly_RB variation_NN than_IN rocuronium_NN ._.
        Furthermore_RB ,_, an_DT atypical_JJ response_NN was_VBD not_RB present_JJ in_IN any_DT
        patient_NN ._. Therefore_RB ,_, we_PRP considered_VBD that_IN our_PRP$ patients_NNS were_VBD a_DT
        population_NN without_IN marked_VBD differences_NNS in_IN plasmatic_JJ
        cholinesterase_NN activity_NN ._.
        In_IN relation_NN to_TO cardiovascular_JJ response_NN ,_, administration_NN
        of_IN mivacurium_NN 200_CD to_TO 300_CD μg_NN /_NN kg_NN in_IN infants_NNS and_CC children_NNS has_VBZ
        demonstrated_VBN minor_JJ changes_NNS or_CC lack_NN of_IN significant_JJ changes_NNS
        in_IN HR_NNP and_CC blood_NN pressure_NN [_NN 14_CD 18_CD 19_CD 23_CD 24_CD ]_NN ._. We_PRP observed_VBD
        an_DT increment_NN in_IN HR_NNP at_IN the_DT first_JJ minute_NN ,_, reaching_VBG the_DT top_NN at_IN
        5_CD min_NN in_IN both_DT groups_NNS ._. Agents_NNS having_VBG varying_VBG cardiovascular_JJ
        effects_NNS were_VBD administered_VBN in_IN addition_NN to_TO and_CC preceding_VBG the_DT
        mivacurium_NN ,_, when_WRB assessing_VBG the_DT cardiovascular_JJ response_NN ._.
        Atropine_NNP administration_NN and_CC combination_NN of_IN fentanyl_NN and_CC
        propofol_NN could_MD certainly_RB have_VB an_DT effect_NN on_IN heart_NN rate_NN and_CC
        blood_NN pressure_NN in_IN our_PRP$ patients_NNS ._. However_RB ,_, a_DT drop_NN in_IN blood_NN
        pressures_NNS indicated_VBN by_IN lower_JJR AUC-SBP_NNP and_CC AUC-DBP_NNP of_IN
        patients_NNS receiving_VBG mivacurium_NN 250_CD μg_NN /_NN kg_NN was_VBD significant_JJ ._.
        The_DT review_NN article_NN of_IN Goudsouzian_NNP states_NNS that_WDT reported_VBD ED_NNP 
        95_CD of_IN mivacurium_NN for_IN infants_NNS ranges_NNS from_IN
        65_CD -_: 94_CD μg_NN /_NN kg_NN [_NN 3_CD ]_NN ._. The_DT dose_NN of_IN 200_CD μg_NN /_NN kg_NN will_MD then_RB be_VB 2_CD to_TO
        3_CD times_NNS the_DT referenced_JJ ED_NNP 
        95_CD ,_, and_CC 250_CD will_MD be_VB 2_CD ._. 5_CD to_TO
        approximately_RB 4_CD times_NNS ._. We_PRP therefore_RB considered_VBD that_IN these_DT
        changes_NNS could_MD be_VB mainly_RB related_VBN to_TO histamine_NN release_NN with_IN
        both_DT doses_NNS ,_, probably_RB more_JJR marked_VBD with_IN the_DT highest_JJS dose_NN ._.
        Fortunately_RB ,_, in_IN most_JJS cases_VBZ the_DT histamine_NN release_NN and_CC
        cardiovascular_JJ changes_NNS have_VBP lacked_VBN clinical_JJ significance_NN [_NN
        25_CD ]_NN ._.
        The_DT TOF-Guard_NNP was_VBD used_VBN to_TO evaluate_VB the_DT neuromuscular_NN
        response_NN ._. Some_DT studies_NNS have_VBP supported_VBN its_PRP$ use_NN by_IN finding_VBG
        that_DT acceleromyography_NN compares_VBZ closely_RB with_IN other_JJ more_RBR
        sophisticated_JJ equipment_NN [_NN 26_CD 27_CD ]_NN ,_, whereas_IN clinical_JJ trials_NNS
        using_VBG the_DT TOF-Guard_NNP to_TO measure_VB neuromuscular_NN function_NN have_VBP
        been_VBN increased_VBN ._. However_RB ,_, it_PRP is_VBZ not_RB yet_RB accepted_VBD as_IN a_DT
        monitor_NN of_IN definitive_JJ studies_NNS of_IN neuromuscular_NN blocking_VBG
        agents_NNS in_IN anesthesia_NN probably_RB because_IN it_PRP does_VBZ not_RB register_VB
        the_DT neuromuscular_NN function_NN in_IN a_DT continuous_JJ fashion_NN ,_, and_CC can_MD
        generate_VB "_'' noise_NN "_'' in_IN the_DT measurement_NN of_IN the_DT effect_NN [_NN 20_CD ]_NN ._.
        Previously_RB ,_, we_PRP utilized_JJ it_PRP to_TO evaluate_VB the_DT pharmacodynamics_NNS
        of_IN rocuronium_NN [_NN 6_CD 28_CD ]_NN ._. When_WRB used_VBN for_IN rocuronium_NN ,_, data_NNS
        acquisition_NN every_DT 5_CD min_NN in_IN the_DT recovery_NN period_NN was_VBD enough_RB
        to_TO model_VB the_DT recovery_NN phase_NN ._. Because_IN of_IN a_DT fast_JJ recovery_NN
        after_IN mivacurium_NN administration_NN ,_, data_NNS acquisition_NN in_IN the_DT
        recovery_NN phase_NN was_VBD now_RB performed_VBN every_DT minute_NN and_CC the_DT
        effect_NN was_VBD also_RB successfully_RB modeled_VBD ,_, and_CC results_NNS agreed_VBD
        with_IN those_DT previously_RB published_VBN in_IN the_DT literature_NN ._. We_PRP
        therefore_RB considered_VBD that_IN ,_, if_IN any_DT ,_, the_DT noise_NN generated_VBN by_IN
        TOF-Guard_NNP measurements_NNS did_VBD not_RB affect_VB data_NNS modeling_NN nor_CC
        results_NNS and_CC conclusions_NNS of_IN the_DT current_JJ study_NN ._. Unfortunately_RB
        and_CC despite_IN its_PRP$ relative_JJ low_JJ cost_NN ,_, capacity_NN to_TO retain_VB data_NNS
        sets_NNS and_CC its_PRP$ easy-to-use_JJ ,_, TOF-Guard_NNP is_VBZ worldwide_NN no_RB longer_RB
        commercially_RB available_JJ ._. It_PRP is_VBZ being_VBG replaced_VBN by_IN the_DT
        manufacturer_NN company_NN with_IN equivalent_NN equipment_NN named_VBD the_DT
        TOF-Watch_NNP series_NN (_( written_VBN personal_JJ communication_NN from_IN
        Biometer_NNP International_NNP A_DT /_NN S_NNP ,_, Odense_NNP ,_, Denmark_NNP ,_, 1999_CD )_) ,_, unable_JJ
        to_TO retain_VB data_NNS and_CC therefore_RB require_VB to_TO be_VB connected_VBN into_IN a_DT
        computer_NN ._.
        Finally_RB ,_, we_PRP simultaneously_RB registered_VBD T_NN and_CC T_NN 4_CD /_NN T_NN 1_CD ._. It_PRP
        has_VBZ been_VBN proposed_VBN that_IN the_DT T_NN 4_CD /_NN T_NN 1_CD is_VBZ more_RBR sensitive_JJ than_IN
        evaluation_NN of_IN any_DT single_JJ twitch_VB of_IN the_DT TOF_NNP response_NN [_NN 29_CD 30_CD
        ]_NN ,_, and_CC does_VBZ not_RB need_VB an_DT established_VBN control_NN ._. By_IN evaluating_VBG
        the_DT T_NN response_NN ,_, significantly_RB faster_JJR OA_NNP times_NNS were_VBD
        identified_VBN with_IN mivacurium_NN 250_CD μg_NN /_NN kg_NN ,_, while_IN all_PDT the_DT T_NN 1_CD /_NN T_NN 4_CD
        were_VBD similar_JJ between_IN the_DT two_CD groups_NNS ._. This_DT controversy_NN
        deserves_VBZ further_JJ investigation_NN ._.
      
      
        Conclusions_NNP
        The_DT maximal_NN effect_NN of_IN mivacurium_NN 250_CD μg_NN /_NN kg_NN was_VBD produced_VBN
        one_CD minute_NN faster_JJR than_IN 200_CD μg_NN /_NN kg_NN ._. However_RB ,_, it_PRP was_VBD
        associated_VBN to_TO a_DT significant_JJ cardiovascular_JJ response_NN ._. We_PRP
        therefore_RB conclude_VBP that_IN the_DT higher_JJR dose_NN does_VBZ not_RB offer_VB a_DT
        satisfactory_JJ clinical_JJ advantage_NN over_IN the_DT lower_JJR dose_NN in_IN
        infants_NNS under_IN general_JJ anesthesia_NN with_IN isoflurane_NN ._.
      
      
        Abbreviations_NNP
        AUC-HR_NNP ,_, AUC-SBP_NNP and_CC AUC-DBP_NNP :_: Respectively_NNP ,_, the_DT area_NN
        under_IN the_DT time-course_JJ of_IN heart_NN rate_NN ,_, systolic_JJ and_CC diastolic_JJ
        blood_NN pressure_NN ;_: b_SYM :_: the_DT slope_NN factor_NN ;_: E_NNP 
        0_CD :_: response_NN at_IN zero_CD time_NN ;_: E_NNP 
        max_NN :_: maximal_NN response_NN ;_: OA_NNP :_: Onset_NNP of_IN
        action_NN ;_: OA_NNP 
        90_CD and_CC OA_NNP 
        100_CD :_: Time_NNP to_TO a_DT block_NN of_IN 90_CD and_CC 99_CD ._. 9_CD %_NN at_IN
        onset_NN of_IN action_NN ,_, respectively_RB ;_: T_NN :_: The_DT first_JJ twitch_VB of_IN the_DT
        TOF_NNP ,_, expressed_VBD as_IN %_NN of_IN control_NN values_NNS ;_: TOF_NNP :_: Train-of-four_NNP ;_:
        T_NN 4_CD /_NN T_NN 1_CD :_: The_DT ratio_NN between_IN the_DT fourth_JJ and_CC the_DT first_JJ stimuli_NNS
        of_IN the_DT TOF_NNP ;_: T_NN 
        10_CD ,_, T_NN 
        25_CD ,_, T_NN 
        50_CD ,_, T_NN 
        75_CD ,_, T_NN 
        90_CD :_: Respectively_NNP ,_, the_DT time_NN to_TO
        spontaneous_JJ recovery_NN of_IN 10_CD ,_, 25_CD ,_, 50_CD ,_, 75_CD and_CC 90_CD %_NN of_IN T_NN ;_: T_NN 4_CD /_NN T_NN 1_CD 
        10_CD ,_, T_NN 4_CD /_NN T_NN 1_CD 
        25_CD ,_, T_NN 4_CD /_NN T_NN 1_CD 
        50_CD ,_, T_NN 4_CD /_NN T_NN 1_CD 
        75_CD ,_, T_NN 4_CD /_NN T_NN 1_CD 
        90_CD :_: Respectively_NNP ,_, the_DT time_NN to_TO
        spontaneous_JJ recovery_NN of_IN 10_CD ,_, 25_CD ,_, 50_CD ,_, 75_CD and_CC 90_CD %_NN of_IN T_NN 4_CD /_NN T_NN 1_CD
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD
      
    
  
